CCCC Projected Dividend Yield
C4 Therapeutics Inc ( NASDAQ : CCCC )C4 Therapeutics is a clinical-stage biopharmaceutical company focused on advancing targeted protein degradation science to develop a new generation of small-molecule medicines to transform how disease is treated. Co.'s primary advanced product candidate, CFT7455, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3 in clinical development for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. Co. is also developing CFT8634, an orally bioavailable Bifunctional Degradation Activating Compounds degrader of a protein target called BRD9, for synovial sarcoma and SMARCB1-deleted solid tumors. 20 YEAR PERFORMANCE RESULTS |
CCCC Dividend History Detail CCCC Dividend News CCCC Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |